NEW YORK – Nova one advisor recently added a research report, US General Anesthesia Drugs market – global industry size, share analysis, market dynamics, market risk factors, market opportunities and challenges. segment forecast and the geographical distribution of the global market, profitability graph and the regional outlook of this business vertical.
Market Size; The global US General Anesthesia Drugs market size was valued at US$ 3.2 Billion in 2020 and is projected to reach US$ 4.6 Billion by 2027, rising at a market growth (CAGR) of 5.2% during the forecast period.
The rising prevalence of cancer, rapid growth in geriatric population, and increasing number of emergency surgeries are some of the major factors driving the growth of the US general anesthesia drugs.
This research report purposes at stressing the most lucrative growth prospects. The aim of the research report is to provide an inclusive valuation of the US General Anesthesia Drugs market and it encompasses thoughtful visions, actualities, industry-validated market findings, historic data, and prognoses by means of appropriate set of assumptions and practice. Global US General Anesthesia Drugs market report aids in comprehending market structure and dynamics by recognizing and scrutinizing the market sectors and predicted the global market outlook.
NOTE: Our report highlights the major issues and hazards that companies might come across due to the unprecedented outbreak of COVID-19.
Request Coronavirus Impact Analysis on This Market@ https://www.novaoneadvisor.com/report/sample/4313
A recent report provides crucial insights along with application based and forecast information in the Global US General Anesthesia Drugs Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the US General Anesthesia Drugs market.
With increasing cases of obesity all over the globe, a need for conducting an in-depth study about this healthcare issue led to the development of this report. Increasing binge eating and consumption of junk foods, neglect towards regular exercise, rising levels of stress, are key market drivers. The report discusses more information about these subjects, with a focus on the rising need for US General Anesthesia Drugs.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period. With healthcare being a sensitive topic, a separate analysis is included that discusses the widespread continuing obesity all over the globe consequently increasing demand for surgical devices.
Highlights of the Report:
In-depth analysis of various insights, namely, US General Anesthesia Drugs Market trends, growth drivers, opportunities, and other related challenges.
Comprehensive details of key market players, their core competencies, and US General Anesthesia Drugs Market share.
The potency of suppliers and buyers to make better business decisions.
Lists out the market size in terms of volume.
Download This Full Research Report, Click Here@ https://www.novaoneadvisor.com/report/checkout/4313
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analyzed and prime business strategies and products that offer high revenue generation capacities were indentified. Key players of the global US General Anesthesia Drugs market are included as given below:
List of KEY PLAYERS in US General Anesthesia Drugs Market Report are:
The US general anesthesia drugs market is dominated by a few established players such as Baxter International Inc. (US), Hikma Pharmaceuticals plc (UK), Pfizer Inc. (US), Piramal Enterprises Limited (India), AbbVie (US), Fresenius SE & Co. KGaA (Germany), Par Pharmaceutical (US), Teva Pharmaceuticals (Israel), Viatris/Mylan (US), Novartis AG (US), Abbott Laboratories (US), AstraZeneca plc (US), F.Hoffmann-La Roche (Switzerland), GlaxoSmithKline plc (UK), Gilead Sciences, Inc. (US), Bayer AG (Germany), Merck & Co., Inc. (Germany), Sanofi (France), Heritage Pharmaceuticals Inc. (US), Akorn (US), and Apotex (Canada). (Total 20 Companies)
Unravelling the Critical Segments
This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:
- By Route of Administration
- Inhalational
- Sevoflurane
- Desflurane
- Isoflurane
- Nitrous Oxide
- Intravenous
- Propofol
- Benzodiazepines
- Ketamine
- Methohexital Sodium
- Others (Etomidate, Fentanyl, Remifentanil)
- Inhalational
- By End User
- Hospitals
- Ambulatory Surgery Centers
- Company Type
- Tier 1 Pharmaceutical Companies
- Tier 2 Pharmaceutical Companies
- Tier 3 Pharmaceutical Companies
Regional Analysis and Forecast
Further, this research study analyses market size, production, consumption and its advancement trends at global, regional, and country level for period 2016 to 2027 and covers following region in its scope:
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- Italy
- France
- Rest of EU
- Asia Pacific
- China
- India
- Japan
- Southeast Asia
- Rest of APAC
- Central & South America
- Brazil
- Argentina
- Rest of Central & South America
- Middle East and Africa
- UAE
- Saudi Arabia
- Rest of MEA
Important years considered for this report:
Historical Years: 2017-2021
Base Year: 2021
Forecast Period: 2021-2027
Impact of COVID-19 on the Healthcare Industry
The COVID-19 pandemic has caused severe impacts on the global economy at various levels and which can be seen on the Healthcare industry as well. The thriving market of health care research and development is expected to exhibit a steep decline in the sales during the lockdown period owing to the shutdown of the manufacturing units, acute shortage in the supply of raw materials and absence of potential manpower. It can be deduced from the current situations brought about by the pandemic that the production, and supply chain activities have experienced minor hurdles. However, the market is projected to gradually recover post-COVID-19, which will present attractive opportunities for sales across various regions of the world in the following years.
Nova one advisor adopted a multidisciplinary approach during the pandemic-era to focus on the growth and development of the US General Anesthesia Drugs Market. The study features insights on the current growth dynamics and the major revenue reforms prevailing in the market as along with the key takeaways over the forecast.
The team of analysts at Nova one advisor are focussing on research and market study to produce different US General Anesthesia Drugs Market forecasts and predictions at both national and international levels. They have considered several leads of information pertaining to the industry like market figures and merger estimations to assess and produce reliable and informative insights on the US General Anesthesia Drugs Market.
Key Questions Covered in the Report
- What is the impact of Covid-19 on the US General Anesthesia Drugs Market?
- What is the CAGR of this market during the forecast period 2021 to 2027?
- How will the market expand through 2027?
- Which top manufacturing companies are leading this market?
- What are the key drivers and trends that will stimulate US General Anesthesia Drugs sales?
- What are the challenges that will affect the sales of this market?
- Which region will remain the most lucrative during the forecast period?
Reasons to Purchase this Report:
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market of various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
Table of Contents
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global US General Anesthesia Drugs Market, By Route of Administration
7.1. US General Anesthesia Drugs Market, By Route of Administration, 2021-2027
7.1.1. Inhalational
7.1.1.1. Market Revenue and Forecast (2016-2027)
7.1.2. Intravenous
7.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 8. Global US General Anesthesia Drugs Market, By End User
8.1. US General Anesthesia Drugs Market, By End User, 2021-2027
8.1.1. Hospitals
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Ambulatory Surgery Centers
8.1.2.1. Market Revenue and Forecast (2016-2027)
Chapter 9. Global US General Anesthesia Drugs Market, Company Type
9.1. US General Anesthesia Drugs Market, Company Type, 2021-2027
9.1.1. Tier 1 Pharmaceutical Companies
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Tier 2 Pharmaceutical Companies
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Tier 3 Pharmaceutical Companies
9.1.3.1. Market Revenue and Forecast (2016-2027)
Chapter 10.Global US General Anesthesia Drugs Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.1.2. Market Revenue and Forecast, by Coating (2016-2027)
10.1.3. Market Revenue and Forecast, by Technology (2016-2027)
10.1.4. Market Revenue and Forecast, by Texture (2016-2027)
10.1.5. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.1.6. Market Revenue and Forecast, by Raw Material (2016-2027)
10.1.7. U.S.
10.1.7.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.1.7.2. Market Revenue and Forecast, by Coating (2016-2027)
10.1.7.3. Market Revenue and Forecast, by Technology (2016-2027)
10.1.7.4. Market Revenue and Forecast, by Texture (2016-2027)
10.1.8. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.1.8.1. Market Revenue and Forecast, by Raw Material (2016-2027)
10.1.9. Rest of North America
10.1.9.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.1.9.2. Market Revenue and Forecast, by Coating (2016-2027)
10.1.9.3. Market Revenue and Forecast, by Technology (2016-2027)
10.1.9.4. Market Revenue and Forecast, by Texture (2016-2027)
10.1.10. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.1.11. Market Revenue and Forecast, by Raw Material (2016-2027)
10.1.11.1.
10.2. Europe
10.2.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.2.2. Market Revenue and Forecast, by Coating (2016-2027)
10.2.3. Market Revenue and Forecast, by Technology (2016-2027)
10.2.4. Market Revenue and Forecast, by Texture (2016-2027)
10.2.5. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.6. Market Revenue and Forecast, by Raw Material (2016-2027)
10.2.7.
10.2.8. UK
10.2.8.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.2.8.2. Market Revenue and Forecast, by Coating (2016-2027)
10.2.8.3. Market Revenue and Forecast, by Technology (2016-2027)
10.2.9. Market Revenue and Forecast, by Texture (2016-2027)
10.2.10. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.10.1. Market Revenue and Forecast, by Raw Material (2016-2027)
10.2.11. Germany
10.2.11.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.2.11.2. Market Revenue and Forecast, by Coating (2016-2027)
10.2.11.3. Market Revenue and Forecast, by Technology (2016-2027)
10.2.12. Market Revenue and Forecast, by Texture (2016-2027)
10.2.13. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.14. Market Revenue and Forecast, by Raw Material (2016-2027)
10.2.14.1.
10.2.15. France
10.2.15.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.2.15.2. Market Revenue and Forecast, by Coating (2016-2027)
10.2.15.3. Market Revenue and Forecast, by Technology (2016-2027)
10.2.15.4. Market Revenue and Forecast, by Texture (2016-2027)
10.2.16. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.16.1. Market Revenue and Forecast, by Raw Material (2016-2027)
10.2.17. Rest of Europe
10.2.17.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.2.17.2. Market Revenue and Forecast, by Coating (2016-2027)
10.2.17.3. Market Revenue and Forecast, by Technology (2016-2027)
10.2.17.4. Market Revenue and Forecast, by Texture (2016-2027)
10.2.18. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.2.18.1. Market Revenue and Forecast, by Raw Material (2016-2027)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.3.2. Market Revenue and Forecast, by Coating (2016-2027)
10.3.3. Market Revenue and Forecast, by Technology (2016-2027)
10.3.4. Market Revenue and Forecast, by Texture (2016-2027)
10.3.5. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.6. Market Revenue and Forecast, by Raw Material (2016-2027)
10.3.7. India
10.3.7.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.3.7.2. Market Revenue and Forecast, by Coating (2016-2027)
10.3.7.3. Market Revenue and Forecast, by Technology (2016-2027)
10.3.7.4. Market Revenue and Forecast, by Texture (2016-2027)
10.3.8. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.9. Market Revenue and Forecast, by Raw Material (2016-2027)
10.3.10. China
10.3.10.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.3.10.2. Market Revenue and Forecast, by Coating (2016-2027)
10.3.10.3. Market Revenue and Forecast, by Technology (2016-2027)
10.3.10.4. Market Revenue and Forecast, by Texture (2016-2027)
10.3.11. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.11.1. Market Revenue and Forecast, by Raw Material (2016-2027)
10.3.12. Japan
10.3.12.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.3.12.2. Market Revenue and Forecast, by Coating (2016-2027)
10.3.12.3. Market Revenue and Forecast, by Technology (2016-2027)
10.3.12.4. Market Revenue and Forecast, by Texture (2016-2027)
10.3.12.5. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.12.6. Market Revenue and Forecast, by Raw Material (2016-2027)
10.3.13. Rest of APAC
10.3.13.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.3.13.2. Market Revenue and Forecast, by Coating (2016-2027)
10.3.13.3. Market Revenue and Forecast, by Technology (2016-2027)
10.3.13.4. Market Revenue and Forecast, by Texture (2016-2027)
10.3.13.5. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.3.13.6. Market Revenue and Forecast, by Raw Material (2016-2027)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.4.2. Market Revenue and Forecast, by Coating (2016-2027)
10.4.3. Market Revenue and Forecast, by Technology (2016-2027)
10.4.4. Market Revenue and Forecast, by Texture (2016-2027)
10.4.5. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.6. Market Revenue and Forecast, by Raw Material (2016-2027)
10.4.7. GCC
10.4.7.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.4.7.2. Market Revenue and Forecast, by Coating (2016-2027)
10.4.7.3. Market Revenue and Forecast, by Technology (2016-2027)
10.4.7.4. Market Revenue and Forecast, by Texture (2016-2027)
10.4.8. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.9. Market Revenue and Forecast, by Raw Material (2016-2027)
10.4.10. North Africa
10.4.10.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.4.10.2. Market Revenue and Forecast, by Coating (2016-2027)
10.4.10.3. Market Revenue and Forecast, by Technology (2016-2027)
10.4.10.4. Market Revenue and Forecast, by Texture (2016-2027)
10.4.11. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.12. Market Revenue and Forecast, by Raw Material (2016-2027)
10.4.13. South Africa
10.4.13.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.4.13.2. Market Revenue and Forecast, by Coating (2016-2027)
10.4.13.3. Market Revenue and Forecast, by Technology (2016-2027)
10.4.13.4. Market Revenue and Forecast, by Texture (2016-2027)
10.4.13.5. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.13.6. Market Revenue and Forecast, by Raw Material (2016-2027)
10.4.14. Rest of MEA
10.4.14.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.4.14.2. Market Revenue and Forecast, by Coating (2016-2027)
10.4.14.3. Market Revenue and Forecast, by Technology (2016-2027)
10.4.14.4. Market Revenue and Forecast, by Texture (2016-2027)
10.4.14.5. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.4.14.6. Market Revenue and Forecast, by Raw Material (2016-2027)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.5.2. Market Revenue and Forecast, by Coating (2016-2027)
10.5.3. Market Revenue and Forecast, by Technology (2016-2027)
10.5.4. Market Revenue and Forecast, by Texture (2016-2027)
10.5.5. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.5.6. Market Revenue and Forecast, by Raw Material (2016-2027)
10.5.7. Brazil
10.5.7.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.5.7.2. Market Revenue and Forecast, by Coating (2016-2027)
10.5.7.3. Market Revenue and Forecast, by Technology (2016-2027)
10.5.7.4. Market Revenue and Forecast, by Texture (2016-2027)
10.5.8. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.5.8.1. Market Revenue and Forecast, by Raw Material (2016-2027)
10.5.9. Rest of LATAM
10.5.9.1. Market Revenue and Forecast, by Vehicle (2016-2027)
10.5.9.2. Market Revenue and Forecast, by Coating (2016-2027)
10.5.9.3. Market Revenue and Forecast, by Technology (2016-2027)
10.5.9.4. Market Revenue and Forecast, by Texture (2016-2027)
10.5.9.5. Market Revenue and Forecast, by Distribution Channel (2016-2027)
10.5.9.6. Market Revenue and Forecast, by Raw Material (2016-2027)
Chapter 11. Company Profiles
11.1. Baxter International Inc. (US)
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Hikma Pharmaceuticals plc (UK)
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Pfizer Inc. (US)
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Piramal Enterprises Limited (India)
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. AbbVie (US),
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Fresenius SE & Co. KGaA (Germany)
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Par Pharmaceutical (US)
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Teva Pharmaceuticals (Israel)
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Viatris/Mylan (US)
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Novartis AG (US)
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
11.11. Abbott Laboratories (US)
11.11.1. Company Overview
11.11.2. Product Offerings
11.11.3. Financial Performance
11.11.4. Recent Initiatives
11.12. AstraZeneca plc (US)
11.12.1. Company Overview
11.12.2. Product Offerings
11.12.3. Financial Performance
11.12.4. Recent Initiatives
11.13. F.Hoffmann-La Roche (Switzerland)
11.13.1. Company Overview
11.13.2. Product Offerings
11.13.3. Financial Performance
11.13.4. Recent Initiatives
11.14. GlaxoSmithKline plc (UK)
11.14.1. Company Overview
11.14.2. Product Offerings
11.14.3. Financial Performance
11.14.4. Recent Initiatives
11.15. Gilead Sciences, Inc. (US)
11.15.1. Company Overview
11.15.2. Product Offerings
11.15.3. Financial Performance
11.15.4. Recent Initiatives
11.16. Bayer AG (Germany)
11.16.1. Company Overview
11.16.2. Product Offerings
11.16.3. Financial Performance
11.16.4. Recent Initiatives
11.17. Merck & Co., Inc. (Germany)
11.17.1. Company Overview
11.17.2. Product Offerings
11.17.3. Financial Performance
11.17.4. Recent Initiatives
11.18. Sanofi (France)
11.18.1. Company Overview
11.18.2. Product Offerings
11.18.3. Financial Performance
11.18.4. Recent Initiatives
11.19. Heritage Pharmaceuticals Inc. (US)
11.19.1. Company Overview
11.19.2. Product Offerings
11.19.3. Financial Performance
11.19.4. Recent Initiatives
11.20. Akorn (US)
11.20.1. Company Overview
11.20.2. Product Offerings
11.20.3. Financial Performance
11.20.4. Recent Initiatives
11.21. Apotex (Canada)
11.21.1. Company Overview
11.21.2. Product Offerings
11.21.3. Financial Performance
11.21.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Complete The Payment and Get the Full Access of Report@ https://www.novaoneadvisor.com/report/checkout/4313
Contact Us:
Nova One Advisor
URL – https://www.novaoneadvisor.com/
Mailing Address: 237 West 35th Street, Suite 605, New York, NY 10001, USA
Any Assistance, Email – sales@novaoneadvisor.com
